Leading clinicians use Elekta technology in clinical research of serious diseaseAtlanta, GA United States — Monday, July 19, 2010
The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO’s 52nd Annual Meeting (October 31 - November 4) at the San Diego Convention Center.
NSCLC, the most common form of lung cancer, arises from a number of causes, including active smoking, passive smoking (secondhand smoke), asbestos and radon exposure. Lung cancer is the leading cause of cancer death in men and women. Each year, primary carcinoma of the lungs affects 93,000 men and 80,000 women in the United States and 86 percent die within five years of diagnosis. The incidence of lung cancer peaks between the ages 55 and 65.1
“The research in which our Lung Cancer Consortium is engaged is completely consistent with ASTRO’s theme this year: Gathering Evidence; Proving Value,” says Joel Goldwein, M.D., Senior Vice President and Director of Medical Affairs for Elekta. "The researchers have made a number of very important discoveries, some of which I believe will be likely to change how SBRT is administered to this challenging group of patients. It doesn't get much more valuable than that."
The four papers featuring Elekta technology are:
The clinicians are affiliated with the University of Würzburg, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital (NKI/AvL), Princess Margaret Hospital / University Health Network, Thomas Jefferson University Hospital and William Beaumont Hospital.
Advanced Elekta SBRT technology used today includes Elekta Axesse™ and Elekta Synergy® S treatment systems and Symmetry™ and Intuity™ software. Symmetry is a breakthrough technology that enables highly accurate, yet completely non-invasive lung tumor treatments without requiring additional intra-fraction radiation imaging. Intuity ensures that not only is the tumor’s position accounted for, but also the position of nearby healthy critical structures. Both innovations contribute to a more patient-friendly and safe treatment.
1Retrieved June 29, 2010 from the Cancer Monthly website: http://www.cancermonthly.com/cancer_basics/lung.asp
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37
Time zone: CET: Central European Time
Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Time zone: ET: Eastern Time